BCM
HAE icon

Bridgeway Capital Management’s Haemonetics HAE Stock Holding History

Bridgeway Capital Management’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-3,800
Closed -$437K – 1315
2019
Q4 		$437K Hold
3,800
– – 0.01% 1037
2019
Q3 		$479K Sell
3,800
-2,300
-38% -$292K 0.01% 975
2019
Q2 		$734K Sell
6,100
-1,000
-14% -$98.4K 0.01% 842
2019
Q1 		$621K Hold
7,100
– – 0.01% 955
2018
Q4 		$710K Buy
+7,100
New +$746K 0.01% 881

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Bridgeway Capital Management's HAE Position: Q1 2020 in Review

Bridgeway Capital Management sold out of Haemonetics (HAE) in Q1 2020, closing a stake of 3,800 shares — an estimated $437K sold.

Bridgeway Capital Management first reported a position in HAE in Q4 2018 and held it in 5 quarters. The position peaked at $734K in Q2 2019. 269 funds tracked by Wall St. Rank hold HAE as of Q1 2020.

  • Bridgeway Capital Management reported no remaining Haemonetics position as of Q1 2020 after selling out during the quarter.
  • Bridgeway Capital Management sold 3,800 Haemonetics shares in Q1 2020, an estimated $437K.
  • Bridgeway Capital Management first reported a position in Haemonetics in Q4 2018 and held it in 5 quarters.
  • Bridgeway Capital Management's Haemonetics position peaked at $734K in Q2 2019.
  • 269 funds tracked by Wall St. Rank held Haemonetics as of Q1 2020.

Based on Bridgeway Capital Management's 13F filing for Q1 2020, filed 15 May 2020.